Lincoln Nadauld, president and CEO of Culmination Bio, leads a company aimed at harnessing the potential of extensive patient data. He discusses the challenges in accessing longitudinal biological and clinical data for drug development. The conversation highlights how partnerships are enhancing diagnostics and therapies with advanced genomic insights. Nadauld also shares insights on revolutionary blood-based cancer diagnostics and the power of real-world data to improve medication accuracy and reduce healthcare costs.

Dr. Derrick Haslem and Dr. Lincoln Nadauld discuss their research on precision oncology in advanced cancer patients, highlighting improved overall survival and lower healthcare costs. They explore the challenges, outcomes, healthcare costs, benefits, integration, and potential of precision medicine in cancer care.